Transplant Surgery »  Meet the Team »  Medical Oncology »  Alan P. Venook, M.D.

Alan P. Venook, M.D.

Professor of Clinical Medicine,
Division of Hematology Oncology
Department of Medicine
Chairman, UCSF Committee on Human Research

Contact Information

Box 1705, UCSF; San Francisco, CA 94143-1705
(415) 353-9888 (appts)
(415) 353-9959 (fax)
venook@cc.ucsf.edu

All Clinic Information
Open Popup
  • Rutgers College, New Brunswick, New Jersey, BA, 1976, Biological Sciences
  • University of California San Francisco, MD, 1980, Medicine
  • University of California San Francisco, Internship, 1981, Internal Medicine
  • University of California, Davis, Residency, 1985, Internal Medicine
  • University of California San Francisco, Fellowship, 1987, Hematology/Oncology
  • American Board of Internal Medicine
  • American Board of Internal Medicine: Medical Oncology - Subspecialty
  • American Board of Internal Medicine: Hematology  - Subspecialty
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • GI Oncology Program
  • The Liver Center at UCSF
  • Anal Cancer
  • Colon Cancer
  • Esophageal Cancer
  • Hepatocellular Carcinoma (Liver Cancer)
  • Liver Metastases
  • Lynch Syndrome
  • Pancreatic Cancer
  • Rectal Cancer
  • Stomach Cancer
  • Anal Cancer
  • Colon Cancer
  • Hepatocellular Carcinoma (Liver Cancer)
  • Liver Metastases
  • Rectal Cancer
  1. Kelley RK, Venook AP. Nonadherence to Imatinib during an Economic Downturn. N Engl J Med. 2010 Aug 5; 363(6):596-8.
  2. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting. J Clin Oncol. 2010 Sep 1; 28(25):3994-4005.
  3. Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl. 2010 Aug; 16(8):925-9.
  4. Lencioni R, Marrero J, Venook A, Ye SL, Kudo M. Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study. Int J Clin Pract. 2010 Jul; 64(8):1034-41.
  5. Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford). 2010 Jun; 12(5):313-20.
  6. Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB. Phase II Study of the Anti-Cytotoxic T-Lymphocyte-Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer. J Clin Oncol. 2010 Jul 20; 28(21):3485-90.
  7. Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010 Mar; 145(3):276-80.
  8. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7.
  9. Engstrom PF, Arnoletti JP, Benson AB, Berlin JD, Berry JM, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Knol JA, Leong LA, Lin E, Mulcahy MF, Rohren E, Ryan DP, Saltz L, Shibata D, Skibber JM, Small W, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma. J Natl Compr Canc Netw. 2010 Jan; 8(1):106-20.
  10. Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):778-831.
  11. Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):838-81.
  12. Kelley R, Venook AP. Drug development in advanced colorectal cancer: challenges and opportunities. Curr Oncol Rep. 2009 May; 11(3):175-85.
  13. Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009 Apr; 7(4):350-91.
  14. Shah U, O'Neil B, Allen J, Goldberg RM, Bernard S, Moore D, Venook AP, Morse MM. A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher. Gastrointest Cancer Res. 2009 Mar; 3(2):45-8.
  15. Fan SK, Venook AP, Lu Y. Design issues in dose-finding Phase I trials for combinations of two agents. J Biopharm Stat. 2009; 19(3):509-23.

X